AstraZeneca (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2019

  1. Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor B superfamily type 1 receptors

    Molecular Pharmacology, Vol. 95, Núm. 2, pp. 222-234

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87

  2. Inhibition of T-Cell activation by the CTLA4-Fc abatacept is sufficient to ameliorate proteinuric kidney disease

    American Journal of Physiology - Renal Physiology, Vol. 312, Núm. 4, pp. F748-F759

  3. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

    British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265

  4. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

2015

  1. A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia

    PLoS ONE, Vol. 10, Núm. 12

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2004

  1. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus

    Journal of Pathology, Vol. 202, Núm. 3, pp. 313-320